Back

Replimune faces securities class action over RP1 trial disclosures

Verifying
  • Investors filed a securities class action against Replimune Group over RP1 disclosures.
  • The lawsuit focuses on single-arm trials and the company’s FDA regulatory strategy.
  • The complaint alleges Replimune misled shareholders about its drug-development approach.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.